Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
Aclarion (NASDAQ: ACON) announced its participation in the State of Spine Surgery Think Tank conference in Cabo San Lucas, June 25-28, 2025. Dr. Kris Radcliff will present the company's NOCISCAN platform, a SaaS solution that uses MR spectroscopy and AI to help identify the source of chronic low back pain.
NOCISCAN is pioneering as the first evidence-supported platform to noninvasively differentiate between painful and nonpainful lumbar spine discs by quantifying chemical biomarkers. The presentation, titled "MR Spectroscopy, Augmented Intelligence, and Low Back Pain - a New Gold Standard," will take place on June 28, 2025, at 10:20 AM.
Aclarion (NASDAQ: ACON) ha annunciato la sua partecipazione alla conferenza State of Spine Surgery Think Tank a Cabo San Lucas, dal 25 al 28 giugno 2025. Il Dr. Kris Radcliff presenterà la piattaforma NOCISCAN dell'azienda, una soluzione SaaS che utilizza la spettroscopia RM e l'intelligenza artificiale per aiutare a identificare la causa del dolore cronico alla parte bassa della schiena.
NOCISCAN è pionieristica come prima piattaforma supportata da evidenze per distinguere in modo non invasivo tra dischi lombari dolorosi e non dolorosi, quantificando biomarcatori chimici. La presentazione, intitolata "Spettroscopia RM, Intelligenza Aumentata e Dolore Lombare - un Nuovo Standard d'Oro", si terrà il 28 giugno 2025 alle 10:20.
Aclarion (NASDAQ: ACON) anunció su participación en la conferencia State of Spine Surgery Think Tank en Cabo San Lucas, del 25 al 28 de junio de 2025. El Dr. Kris Radcliff presentará la plataforma NOCISCAN de la empresa, una solución SaaS que utiliza espectroscopía de RM y IA para ayudar a identificar la fuente del dolor lumbar crónico.
NOCISCAN es pionera como la primera plataforma respaldada por evidencia que diferencia de forma no invasiva entre discos lumbares dolorosos y no dolorosos cuantificando biomarcadores químicos. La presentación, titulada "Espectroscopía de RM, Inteligencia Aumentada y Dolor Lumbar - un Nuevo Estándar de Oro", se realizará el 28 de junio de 2025 a las 10:20 AM.
Aclarion (NASDAQ: ACON)은 2025년 6월 25일부터 28일까지 카보산루카스에서 열리는 State of Spine Surgery Think Tank 회의에 참여한다고 발표했습니다. Dr. Kris Radcliff가 회사의 NOCISCAN 플랫폼을 소개할 예정이며, 이 플랫폼은 MR 분광법과 AI를 활용해 만성 요통의 원인을 파악하는 SaaS 솔루션입니다.
NOCISCAN은 화학적 바이오마커를 정량화하여 통증이 있는 요추 디스크와 통증이 없는 디스크를 비침습적으로 구분하는 최초의 근거 기반 플랫폼으로 선도적입니다. "MR 분광법, 증강 지능 및 요통 - 새로운 골드 스탠다드"라는 제목의 발표는 2025년 6월 28일 오전 10시 20분에 진행됩니다.
Aclarion (NASDAQ : ACON) a annoncé sa participation à la conférence State of Spine Surgery Think Tank à Cabo San Lucas, du 25 au 28 juin 2025. Le Dr Kris Radcliff présentera la plateforme NOCISCAN de l'entreprise, une solution SaaS qui utilise la spectroscopie RM et l'intelligence artificielle pour aider à identifier la source des douleurs lombaires chroniques.
NOCISCAN est pionnière en tant que première plateforme étayée par des preuves permettant de différencier de manière non invasive les disques lombaires douloureux des non douloureux en quantifiant des biomarqueurs chimiques. La présentation, intitulée "Spectroscopie RM, Intelligence Augmentée et Douleur Lombaire – un Nouveau Standard d’Or", aura lieu le 28 juin 2025 à 10h20.
Aclarion (NASDAQ: ACON) kündigte seine Teilnahme an der State of Spine Surgery Think Tank-Konferenz in Cabo San Lucas vom 25. bis 28. Juni 2025 an. Dr. Kris Radcliff wird die NOCISCAN-Plattform des Unternehmens vorstellen, eine SaaS-Lösung, die MR-Spektroskopie und KI nutzt, um die Ursache chronischer Rückenschmerzen zu identifizieren.
NOCISCAN ist wegweisend als die erste evidenzbasierte Plattform, die schmerzende von nicht schmerzenden Lendenwirbelscheiben nicht-invasiv durch Quantifizierung chemischer Biomarker unterscheidet. Die Präsentation mit dem Titel "MR-Spektroskopie, Augmentierte Intelligenz und Rückenschmerzen – ein Neuer Goldstandard" findet am 28. Juni 2025 um 10:20 Uhr statt.
- None.
- None.
Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank
BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of Spine Surgery Think Tank, taking place in Cabo San Lucas, June 25-28, 2025.
Renowned spine surgeon Dr. Kris Radcliff will present Aclarion's groundbreaking platform, NOCISCAN, highlighting its innovative approach to noninvasively identify objective biomarkers of discogenic pain. Dr. Radcliff will also discuss how he has integrated NOCISCAN into his practice to develop more personalized, effective surgical strategies for his patients with chronic low back pain.
“The State of Spine conference brings together the top thought leaders in spine care, and having Dr. Radcliff present NOCISCAN underscores the growing interest in our platform’s clinical and commercial value,” said Ryan Bond, Chief Strategy Officer. “Dr. Radcliff has successfully integrated NOCISCAN into daily clinical practice and his real-world insights will reinforce the scalability of our technology and its potential to become the standard of care for chronic low back pain.”
Details of the Presentation:
- Title: MR Spectroscopy, Augmented Intelligence, and Low Back Pain - a New Gold Standard
- Date: Saturday, June 28, 2025
- Time: 10:20 AM
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.
For a copy of the NOCISCAN presentation, please email: info@aclarion.com
To find a NOCISCAN center, view our site map here.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
When and where will Aclarion (ACON) present at the State of Spine Surgery Think Tank 2025?
What is Aclarion's NOCISCAN technology used for?
Who will present Aclarion's NOCISCAN technology at the spine conference?
What is the market potential for Aclarion's NOCISCAN technology?
